APLS - Apellis Pharmaceuticals, Inc.
After hours:
Chart Events
Commodity Channel Index
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 86.97 |
| Open | 87.19 |
| Bid | 85.00 x 800 |
| Ask | 86.95 x 800 |
| Day's Range | 85.39 - 87.64 |
| 52 Week Range | 37.66 - 94.45 |
| Volume | |
| Avg. Volume | 1,691,006 |
| Market Cap | 10.121B |
| Beta (5Y Monthly) | 1.23 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.32 |
| Earnings Date | Aug 07, 2023 - Aug 11, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 103.53 |
Fair Value
Related Research
ZacksApellis' (APLS) Study on Pegcetacoplan to Treat ALS Fails
Apellis' (APLS) phase II MERIDIAN study on pegcetacoplan for the treatment of amyotrophic lateral sclerosis fails to meet primary and key secondary endpoints.
American City Business JournalsApellis stops pursuing ALS drug approval after trial failure
Apellis Pharmaceuticals Inc. is stopping work on a drug for amyotrophic lateral sclerosis, or ALS, after it failed in a midstage trial.
GlobeNewswireApellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS
WALTHAM, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Phase 2 MERIDIAN study investigating systemic pegcetacoplan for the treatment of amyotrophic lateral sclerosis (ALS) did not meet its primary endpoint of the Combined Assessment of Function and Survival (CAFS) rank score at Week 52. The study also did not meet key secondary efficacy endpoints. Systemic pegcetacoplan was well tolerated in the study, and the data were consistent w
Motley FoolWhy These 3 Nasdaq Stocks Buckled Today
The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today.
Simply Wall St.Analysts' Revenue Estimates For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Are Surging Higher
Celebrations may be in order for Apellis Pharmaceuticals, Inc. ( NASDAQ:APLS ) shareholders, with the analysts...
- Simply Wall St.
Apellis Pharmaceuticals First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags
Apellis Pharmaceuticals ( NASDAQ:APLS ) First Quarter 2023 Results Key Financial Results Revenue: US$44.8m (up 212...
- GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to 13 new employees with a grant date of May 1, 2023, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2022 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company. Th
Investor's Business DailyApellis Obliterates Sales Expectations; Is A Takeover In The Cards?
Apellis' new eye drug, Syfovre, crushed expectations in its first quarter post launch, sending APLS stock to a record high.
BenzingaApellis Pharma's Newly Approved Drug Exceeds Sales Projections, Bullish Analyst Raises Expectations
Apellis Pharmaceuticals Inc (NASDAQ: APLS) reported Q1 revenues of $44.8 million, surpassing the consensus of $26.10 million and $14.38 million a year ago. The company reported an EPS loss of $(1.56), higher than $(1.42) a year ago and missing the consensus of $(1.46). Needham writes that Syfovre's sales of $18.4 million were well above their estimate of $5 million and the Street's $1.5 million estimates. The analyst has raised the price target to $110 from $80, with a Buy rating. The management
- Thomson Reuters StreetEvents
Q1 2023 Apellis Pharmaceuticals Inc Earnings Call
Q1 2023 Apellis Pharmaceuticals Inc Earnings Call
ZacksApellis (APLS) Q1 Earnings Miss, Empaveli & Syfovre Fuel Growth
Apellis Pharmaceuticals' (APLS) loss in the first quarter is wider than estimates. Empaveli and Syfovre boost product revenues for the company.
ZacksApellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates
Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -9.86% and 71.90%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results
Generated U.S. net product revenues of $18.4 million for SYFOVRE™ (pegcetacoplan injection) and $20.4 million for EMPAVELI® (pegcetacoplan) SYFOVRE launched in the U.S. as the first and only treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD)Validation received for marketing applications for intravitreal pegcetacoplan in the EU, Canada, Australia, the United Kingdom, and Switzerland; decisions expected in the first half of 2024 Cash and cash equivalents of $
- GlobeNewswire
Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference
WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will present at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023, at 3:40 p.m. PT. The event will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available
Motley FoolWhy Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today
With earnings season in full swing, biotechnology stocks were volatile today. Apellis Pharmaceuticals' (NASDAQ: APLS) stock, for instance, dipped by as much as 8.5% in early-morning trading Monday before rallying in the afternoon session. Viking Therapeutics (NASDAQ: VKTX) also joined the bull parade today, with its stock first rising by 7% in the early portion of Monday's session before cooling off to finish up by approximately 3.8%.
ZacksDenali Therapeutics Inc. (DNLI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Denali Therapeutics Inc. (DNLI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results
WALTHAM, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will host a conference call and webcast to discuss its first quarter 2023 financial results on Thursday, May 4, 2023, at 4:30 p.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the “Events an
ZacksApellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Apellis Pharmaceuticals, Inc. (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insider Monkey11 Best Mid-Cap Healthcare Stocks To Buy Now
In this article, we discuss 11 best mid-cap healthcare stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Mid-Cap Healthcare Stocks To Buy Now. The healthcare industry outlook is currently uncertain due to a combination of factors such as economic troubles, a shortage of healthcare workers, […]
- GlobeNewswire
Apellis Presents Phase 3 Functional Analyses of SYFOVRE™ (pegcetacoplan injection) for Geographic Atrophy
Showed visual function and quality-of-life benefits in patients with extrafoveal lesionsSlowed the loss of retinal pigmented epithelial and photoreceptor cells, both of which are required for visual functionEight abstracts, including three oral presentations, highlighted at ARVO annual meeting WALTHAM, Mass., April 23, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced post hoc analyses from the 24-m
- GlobeNewswire
Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy
Applications are under review in Canada, Australia, the United Kingdom, and SwitzerlandApproval decisions expected in the first half of 2024 WALTHAM, Mass., April 21, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company has received validation of its marketing applications by regulatory authorities in Canada, Australia, the United Kingdom, and Switzerland for intravitreal pegcetacoplan
TipRanksThese 2 Red-Hot Stocks Could Reach New Highs, Says Goldman Sachs
If there’s one piece of consistent advice that every investor gets, it’s to never try to ‘time’ the market. Don’t try to buy or sell just at the stock’s inflection point when the momentum turns, because those turning points are impossible to predict. However, when it comes to the stock’s momentum during an upward run, it’s an entirely different tale altogether. Buying in while a stock is on a red-hot run, building momentum, is not only possible, it’s far easier than trying to time a turning poin
- GlobeNewswire
Apellis Partners with Acclaimed Actor Henry Winkler to Raise Awareness of Geographic Atrophy (GA) for the GA Won’t Wait™ Campaign
GA is an advanced form of age-related macular degeneration (AMD) and a leading cause of blindness that impacts approximately one million AmericansWinkler and his family saw firsthand the impact of vision loss by caring for his father-in-law who was living with AMDCampaign encourages older adults to monitor and discuss vision changes with an eye doctor A Media Snippet accompanying this announcement is available by clicking on the image or link below: WALTHAM, Mass., April 17, 2023 (GLOBE NEWSWIRE
ZacksStrength Seen in Apellis Pharmaceuticals, Inc. (APLS): Can Its 16.3% Jump Turn into More Strength?
Apellis Pharmaceuticals, Inc. (APLS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
BenzingaWhy Apellis Pharmaceuticals Stock Is Soaring Today
Rare disease-focused Apellis Pharmaceuticals Inc (NASDAQ: APLS) is reportedly drawing takeover interest from large drugmakers. The company is in talks with advisers to consider its options amid the interest, Bloomberg reported citing people familiar with the matter. Apellis may also consider seeking partnerships or licensing agreements for some of its ophthalmology products, the report added. Deliberations are ongoing, and there's no certainty they will lead to a transaction. In February, the FD